<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480256</url>
  </required_header>
  <id_info>
    <org_study_id>SHR6390-Id</org_study_id>
    <nct_id>NCT03480256</nct_id>
  </id_info>
  <brief_title>Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer</brief_title>
  <official_title>Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and tolerability of SHR6390 combined with
      pyrotinib in the patients with Her-2 positive advanced gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>SHR6390 combined with pyrotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390</intervention_name>
    <description>SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer</description>
    <arm_group_label>SHR6390 combined with pyrotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients definitely diagnosed by pathology as Her2 positive stage III/IV gastric
             cancer

          -  18-75 years old, ECOG PS:0-1,Life expectancy of more than12 weeks;

          -  Patients treated with systematic treatment to metastatic disease then experienced
             progressive disease

          -  Patients with at least one evaluable or measurable disease per RECIST v1.1

          -  Main organs function is normal;

          -  Patients should be voluntary and sign the informed consent before taking part in the
             study;

        Exclusion Criteria:

          -  • Patients who have uncontrollable effusion with clinical symptoms such as severe
             pleural effusion and peritoneal effusion;

               -  A variety of factors that affect oral medication (such as inability to swallow,
                  gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.)

               -  Patients who have steroid treatment for more than 30 days or need long-term
                  steroid treatment;

               -  Patients who had previously received chemotherapy，radiotherapy,
                  hormonotherapy,surgery,targeted therapy(including Trastuzumab) within 2 weeks
                  ;patients who had previously received nitrosourea or Mitomycin with 6 weeks;

               -  Previous treatment-related adverse events did not recover to less than 2 levels
                  except hair loss or other conditions that did not affect the enrollment according
                  to investigators;

               -  Patients who have participated in other anticancer drug clinical trials within 4
                  weeks except that trial is observational or at follow up stage;

               -  Patients who have uncontrollable hypomagnesemia or hypokalemia;

               -  Patients with untreated or symptomatic brain metastasis;

               -  Patients with malignant tumors within 5 years, except for basal cell
                  carcinoma,squamous skin cancer and cervical carcinoma in situ;

               -  Patients who are being treated with any other anticancer strategies;

               -  Patients with allergic constitution or being allergic to any element in the study
                  drugs;

               -  Patients with definite gastrointestinal bleeding tendency, including: active
                  ulcer lesions with OB(++);melena or haematemesis history within 2 months;
                  patients with OB(+) but without tumor resection need gastroscopy. If there is
                  active bleeding, it's not suitable for this trial;

               -  Patients with active infection, including tuberculosis;

               -  Patients with immunodeficiency, including HIV positive or other acquired,
                  congenital immunodeficiency disease, or organ transplant history;

               -  Patients who have had severe cardiac disease within six months, including acute
                  coronary syndrome, arrhythmias that require medication or with clinical
                  significance, or need continuous medication that may cause QT extension, acute
                  myocardial infarction,heart failure,and any other condition that is not suitable
                  for this experiment according to the investigators;

               -  Patients who are pregnant or breast feeding;

               -  Patients who don't agree on contraception; Patients with concomitant diseases
                  which could seriously endanger themselves or those who won't complete the study
                  according to investigators such as hypertension, severe diabetes and thyroid
                  diseases;

               -  Patients with bad addiction such as excessive drinking or smoking;

               -  Patients with definite mental disorder, including epilepsy and dementia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jifang Gong</last_name>
    <phone>13683208528</phone>
    <email>goodjf@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of GI Oncology, Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jifang Gong, MD</last_name>
      <phone>861088196561</phone>
      <email>gongjifang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lin Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Head of Department of Gastrointestinal Oncology,Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>SHR6390</keyword>
  <keyword>Pyrotinib</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>Her-2 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

